News & Updates

CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.

Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.

Partial enteral nutritional (PEN) therapy shows potential in the long-term management of mild paediatric Crohn’s disease, helping to avoid the use of corticosteroids and prevent side effects commonly observed with other inflammatory bowel disease therapies, according to a study presented at the virtual Crohn's & Colitis Congress.

Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

In patients with inflammatory bowel disease (IBD), erectile and sexual dysfunction (SD) are significantly associated with psychological factors, but IBD severity appears to have no impact on such conditions, suggests a recent study. Likewise, the type of medication used to treat the underlying disease has no influence on SD development.

The addition of 5-aminosalicylic acid (5-ASA) to standard corticosteroid treatment did not improve outcomes in patients hospitalized with acute severe ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2022.